📋 TANGO THERAPEUTICS, INC. (TNGX) - Financial Results
Filing Date: 2026-08-11
Accepted: 2026-08-11 07:20:34
Event Type: Financial Results
Event Details:
TANGO THERAPEUTICS, INC. (TNGX) Reports the reporting period Financial Results
TANGO THERAPEUTICS, INC. (TNGX) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: 3181
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 345558
stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of vopimetostat + RAS(ON) inhibitors in pancreatic cancer to be presented at 2026 ESMO Congress Key appointments further position Company for late
stage development and commercialization: Robert Azelby, Chairman of the Board of Directors and Fatma Ocak, Chief Commercialization Officer Cash position of $
0 billion as of June 30, 2026 BOSTON, August 11, 2026 (GLOBE NEWSWIRE)
📋 TANGO THERAPEUTICS, INC. (TNGX) - Financial Results
Filing Date: 2026-08-11
Accepted: 2026-08-11 07:20:34
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: